RE:anyone know?? Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of September 6, 2019, Brandon Moreno resigned as the Chief Financial Officer of Nobilis Health Corp. (the “Company”) and Marissa Arreola resigned as the Chief Legal Officer of the Company.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported, on November 15, 2018, Nobilis Health Corp. (the “Company”) received a notice from the NYSE American LLC (“NYSE”) that the Company was not in compliance with NYSE’s continued listing standards under the timely filing criteria established in Section 1007 of the NYSE American Company Guide, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the three months ended September 30, 2018. Under NYSE rules, the Company was provided a six-month period to correct its filing delinquency and requested to submit a plan of compliance addressing how it intended to regain compliance with the continued listing standards. On May 16, 2019, the Company was notified by NYSE that NYSE Regulation had accepted the Company’s plan to regain compliance with the continued listing standards and granted an extension of the cure period through August 31, 2019, subject to periodic review by NYSE Regulation for compliance with adherence to the milestones set forth in the Company’s plan.
On September 3, 2019, the Company received a notice from the NYSE that, based on the foregoing, the Company’s common shares were subject to delisting proceedings. Although the NYSE provided the Company limited rights to seek a review of such determination within seven days after receiving the notice, the Company has elected not to seek any such review or otherwise appeal the NYSE’s determination. Trading in the Company’s common shares was suspended following the close of the NYSE market on September 3, 2019. At this time, the Company expects that the NYSE could file a Form 25 to delist the Company’s common shares as early as September 11, 2019, following the conclusion of the seven-day review and appeal period, which filing would become effective with respect to the delisting on September 23, 2019. However, the Form 25 filing will not cause the removal of the Company’s common shares from registration under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company will remain subject to the periodic reporting requirements of the Exchange Act.
The Company expects that its common shares will become eligible for quotation on the over-the-counter markets, although there is no assurance as to when trading may commence or that an active market in the common shares will develop.
I'd say it's just about over for them based on today's 8-K